|
US5652258A
(en)
*
|
1995-05-30 |
1997-07-29 |
Gliatech, Inc. |
2-(4-imidazoyl) cyclopropyl derivatives
|
|
US6008240A
(en)
*
|
1997-12-15 |
1999-12-28 |
Gliatech, Inc. |
2-(1H-4(5)-imidazoyl) cyclopropyl derivatives
|
|
JP2002534511A
(ja)
|
1999-01-18 |
2002-10-15 |
ノボ ノルディスク アクティーゼルスカブ |
置換型イミダゾール、それらの調製及び使用
|
|
US7265115B2
(en)
|
1999-01-29 |
2007-09-04 |
Abbott Laboratories |
Diazabicyclic CNS active agents
|
|
US6908926B1
(en)
|
1999-04-16 |
2005-06-21 |
Novo Nordisk A/S |
Substituted imidazoles, their preparation and use
|
|
US6114350A
(en)
*
|
1999-04-19 |
2000-09-05 |
Nen Life Science Products, Inc. |
Cyanine dyes and synthesis methods thereof
|
|
US6437147B1
(en)
|
2000-03-17 |
2002-08-20 |
Novo Nordisk |
Imidazole compounds
|
|
US6610721B2
(en)
|
2000-03-17 |
2003-08-26 |
Novo Nordisk A/S |
Imidazo heterocyclic compounds
|
|
WO2002013821A1
(en)
|
2000-08-17 |
2002-02-21 |
Gliatech, Inc. |
Novel alicyclic imidazoles as h3 agents
|
|
AU2001283573A1
(en)
*
|
2000-08-21 |
2002-03-04 |
Gliatech, Inc. |
The use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity
|
|
AU2002256967A1
(en)
*
|
2000-10-30 |
2002-09-12 |
Schering Corporation |
Treating or reducing the risk of cardiovascular disease
|
|
CA2477391A1
(en)
*
|
2002-03-01 |
2003-09-12 |
Denis Schrier |
Method of treating osteoarthritis
|
|
EP1720847A1
(en)
*
|
2004-02-02 |
2006-11-15 |
Pfizer Products Incorporated |
Histamine-3 receptor modulators
|
|
US7902191B2
(en)
|
2004-02-25 |
2011-03-08 |
Eli Lilly And Company |
Histamine H3 receptor antagonists, preparation and therapeutic uses
|
|
SI1735278T1
(sl)
|
2004-04-01 |
2010-05-31 |
Lilly Co Eli |
Agenti histamin h receptorja priprava in terapevtska uporaba
|
|
AU2005252178B2
(en)
*
|
2004-06-02 |
2011-04-21 |
Eli Lilly And Company |
Histamine H3 receptor agents, preparation and therapeutic uses
|
|
ES2534605T3
(es)
|
2004-08-23 |
2015-04-24 |
Eli Lilly And Company |
Agentes receptores de la histamina H3, preparación y usos terapéuticos
|
|
US7846950B2
(en)
|
2004-10-18 |
2010-12-07 |
Eli Lilly And Company |
Histamine H3 receptor inhibitors, preparation and therapeutic uses
|
|
AU2006227815B2
(en)
|
2005-03-17 |
2011-09-22 |
Eli Lilly And Company |
Pyrrolidine derivatives as histamine H3 receptor antagonists
|
|
AU2006232871B9
(en)
|
2005-04-01 |
2011-11-24 |
Eli Lilly And Company |
Histamine H3 receptor agents, preparation and therapeutic uses
|
|
EP1707203A1
(en)
|
2005-04-01 |
2006-10-04 |
Bioprojet |
Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
|
|
EP1717233A1
(en)
*
|
2005-04-29 |
2006-11-02 |
Bioprojet |
Histamine H3-receptor ligands and their therapeutic application
|
|
EP1717235A3
(en)
|
2005-04-29 |
2007-02-28 |
Bioprojet |
Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
|
|
CA2622597A1
(en)
*
|
2005-09-15 |
2007-03-22 |
Banyu Pharmaceutical Co., Ltd. |
Histamine h3 agonist for use as therapeutic agent for lipid/glucose metabolic disorder
|
|
EP1942104A1
(en)
|
2006-12-20 |
2008-07-09 |
sanofi-aventis |
Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
|
|
WO2010084160A1
(en)
|
2009-01-21 |
2010-07-29 |
Oryzon Genomics S.A. |
Phenylcyclopropylamine derivatives and their medical use
|
|
RU2602814C2
(ru)
|
2009-09-25 |
2016-11-20 |
Оризон Дженомикс С.А. |
Лизинспецифические ингибиторы деметилазы-1 и их применение
|
|
US8946296B2
(en)
|
2009-10-09 |
2015-02-03 |
Oryzon Genomics S.A. |
Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
|
|
WO2011106574A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Inhibitors for antiviral use
|
|
WO2011106573A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
|
|
RS55348B1
(sr)
|
2010-04-19 |
2017-03-31 |
Oryzon Gnomics S A |
Inhibitori lizin specifične demetilaze-1 i njihova upotreba
|
|
WO2012013728A1
(en)
|
2010-07-29 |
2012-02-02 |
Oryzon Genomics S.A. |
Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
|
|
EP2598480B1
(en)
|
2010-07-29 |
2019-04-24 |
Oryzon Genomics, S.A. |
Cyclopropylamine derivatives useful as lsd1 inhibitors
|
|
US9061966B2
(en)
|
2010-10-08 |
2015-06-23 |
Oryzon Genomics S.A. |
Cyclopropylamine inhibitors of oxidases
|
|
WO2012072713A2
(en)
|
2010-11-30 |
2012-06-07 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
|
|
WO2012107498A1
(en)
|
2011-02-08 |
2012-08-16 |
Oryzon Genomics S.A. |
Lysine demethylase inhibitors for myeloproliferative disorders
|
|
MX356344B
(es)
|
2011-10-20 |
2018-05-23 |
Oryzon Genomics Sa |
Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1.
|
|
RU2668952C2
(ru)
|
2011-10-20 |
2018-10-05 |
Оризон Дженомикс, С.А. |
(гетеро)арилциклопропиламины в качестве ингибиторов lsd1
|
|
WO2013151982A1
(en)
|
2012-04-03 |
2013-10-10 |
Arena Pharmaceuticals, Inc. |
Methods and compounds useful in treating pruritus, and methods for identifying such compounds
|